Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory ...

Werewolf Therapeutics (HOWL) provided a business update and outlined its strategic outlook and expected milestones for 2025. “2024 was a year of execution for Werewolf in which we reported data ...

WATERTOWN, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical ...

The stakes weren’t especially high, as Werewolf by Night isn’t about to be the next Steve Rogers, but the special stands on its own. Giacchino manages to mash up the look and feel of a ’30s ...

Werewolf Therapeutics provided a business update highlighting key milestones for 2025 regarding its clinical development programs. The company is expecting to release data from the Phase 1/1b ...

(MENAFN- GlobeNewsWire - Nasdaq) – Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on ...

WATERTOWN, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...

Dog owners are advised to avoid the chews. The UK vets have issued an urgent warning to dog owners about a recalled toy that could cause a rare condition known as "werewolf syndrome." The warning ...